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Abstract
The use of radiolabeled choline as a positron emission tomography (PET) agent for imaging primary tumors in the
prostate has been evaluated extensively over the past two decades. There are, however, conflicting reports of its
sensitivity and the relationship between choline PET imaging and disease staging is not fully understood. Moreover,
relatively few studies have investigated the correlation between tracer uptake and histological tumor grade. This
work quantified 18F-fluorocholine in tumor and healthy prostate tissue using pharmacokinetic modeling and
stratified uptake parameters by histology grade. Additionally, the effect of scan time on the estimation of the
kinetic exchange rate constants was evaluated, and the tracer influx parameters from full compartmental analysis
were compared to uptake values quantified by Patlak and standardized uptake value (SUV) analyses.
18F-fluorocholine was administered as a 222 MBq bolus injection to ten patients with biopsy-confirmed prostate
tumors, and dynamic PET data were acquired for 60 min. Image-derived arterial input functions were scaled by
discrete blood samples, and a 2-tissue, 4-parameter model accounting for blood volume (2T4k+Vb) was used to
perform fully quantitative compartmental modeling on tumor, healthy prostate, and muscle tissue. Subsequently, all
patients underwent radical prostatectomy, and histological analyses were performed on the prostate specimens;
kinetic parameters for tumors were stratified by Gleason score. Correlations were investigated between
compartmental K1 and Ki parameters and SUV and Patlak slope; the effect of scan time on parameter bias was also
evaluated.
Results: Choline activity curves in seven tumors, eight healthy prostate regions, and nine muscle regions were
analyzed. Net tracer influx was generally higher in tumor relative to healthy prostate, with the values in the highest
grade tumors markedly higher than those in lower grade tumors. Influx terms from Patlak and full compartmental
modeling showed good correlation within individual tissue groups. Kinetic parameters calculated from the entire
60-min scan data were accurately reproduced from the first 30 min of acquired data (R2 ≈ 0.9).
Conclusions: Strong correlations were observed between Ki and Patlak slope in tumor tissue, and K1 and SUV were
also correlated but to a lesser degree. Reliable estimates of all kinetic parameters can be achieved from the first
30 min of dynamic 18F-choline data. Although SUV, K1, Ki, and Patlak slope were found to be poor differentiators of
low-grade tumor compared to healthy prostate tissue, they are strong indicators of aggressive disease.
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Background
Prostate cancer (PCa) is common in the USA and is the
second leading cause of cancer death in men. In 2015,
220,800 American men were diagnosed and 27,540 are ex-
pected to die from the disease [1]. Despite its prevalence,
prognoses are generally good for this disease but accurate
diagnoses are critical, as the therapeutic options depend on
the aggressiveness and potential progression of the disease.
Clinically, most prostate cancers are detected first by a
prostate-specific antigen (PSA) blood test or digital rec-
tal exam and are confirmed through subsequent biopsy.
Once confirmed, the patient will undergo diagnostic im-
aging procedures to assess the spread of the disease and
plan treatment. Common imaging modalities include
transrectal ultrasound, MRI, and PET/CT. MRI sessions
generally consist of T1- and T2-weighted, DWI (diffu-
sion-weighted imaging), and sometimes DCE (dynamic
contrast enhanced) and spectroscopy sequences.
Molecular imaging with PET has several benefits due
to the ability to target specific underlying biological pro-
cesses like increased metabolism, upregulated protein
and phospholipid synthesis, expression of androgen re-
ceptors and membrane proteins, or the osteoblastic reac-
tion adjacent to metastases in the bone marrow [2].
Clinically, routine PET imaging is performed with 18F-
fluorodeoxyglucose, but this has shown limited utility
for detecting PCa tumors [3, 4]. Improvements in tumor
uptake have been reported for other tracers including
11C- and 18F-choline [3, 5–7], 11C-acetate [8–10], 11C-
methionine [11, 12], and 18F-fluorodihydrotestosterone
[13, 14]. However, these tracers have demonstrated rela-
tively low specificity due to uptake in normal prostate
tissue and benign lesions including prostatitis, high-
grade intraepithelial neoplasia, or benign prostatic
hyperplasia (BPH) [15, 16]. Consequently, recent focus
has shifted to monitoring the expression of prostate-
specific membrane antigen (PSMA), in which elevated
levels have been histologically correlated with PCa
tumor progression [17], androgen independence [18],
and metastasis [19]. PET agents have been developed as
radiolabeled PSMA analogs like 68Ga-PSMA [20, 21] or
the PSMA inhibitors 18F-DCFBC [22–24] and 18F-
DCFPyL [25]. These new, specific tracers, with high
tumor to background contrast, are extremely promising
and are being used more frequently, particularly for dis-
tant metastases and recurrence. Notwithstanding the
growing interest in these novel tracers, 18F-Fluorodexox-
yglucose (FDG) and choline are still the most clinically
used PET tracers clinically for prostate cancer.
Choline has a strong uptake in the primary prostate
tumor, even though it has not been shown to be highly
specific, since benign prostatic hyperplasia also shows
high uptake. Nevertheless, PET imaging of high choline
uptake could be used to guide or support biopsy and
surgery of primary prostate cancer. Biopsy procedures,
especially of prostate tissue, can cause many issues in-
cluding patient discomfort and infection. False negative
results are also common, which may lead to a repeat
biopsy and incorrect diagnosis. Incorporating imaging at
an earlier point in the clinical routine can potentially
improve patient management.
Radiolabeled choline has been used as a PET agent in
humans for 20 years [26], and the prostate was among
the first imaging targets [27]. Over the years, many stud-
ies have been conducted investigating various aspects of
its clinical utility including its efficacy for detecting
primary tumors and systemic involvement [28, 29], pre-
operative staging and pelvic lymphadenopathy [30–32],
post-therapy biochemical recurrence and correlations
with PSA [33, 34], performance relative to FDG and
other PET tracers [3, 35], MRI [36, 37] and MR spec-
troscopy [38], and quantitative evaluations of tracer
kinetics in tissue [39–41]. Choline standardized uptake
value (SUV) has been studied extensively, and there are
many studies reporting the performance of choline for
detecting patients with biopsy-confirmed prostate
tumors, though with somewhat controversial results
concerning the reported detection sensitivities [16, 42].
However, there are only a limited number of studies
which have correlated choline uptake with histological
tumor grade, in terms of histologic grading and Gleason
score [28, 43, 44]. There are even fewer studies which
have modeled the tracer kinetics and investigated those
relationships with tissue grade [40] and none to our
knowledge using the 18F-labeled derivative.
The aim of this study is to investigate the pharmaco-
kinetics of 18F-fluoromethylcholine in various tissues,
including pathology-confirmed primary prostate tumors
and healthy prostate tissue, and perform a lesion-based
correlation of quantified choline uptake with tumor
grade. In particular, compartmental modeling was per-
formed, and tissue parameters were stratified by Gleason
score. Additionally, the relationships between tracer
perfusion/extraction and influx compartmental rate
constants were evaluated between SUV and Patlak linear
regression analyses. The effect of scan time on kinetic
parameter bias was also assessed.
While the immediate purpose of this work is to inves-
tigate the correlation of choline uptake kinetics with
histologic tumor grade, it also provides the validation of
methods that could be used with other tracers such as
PSMA, which may offer an improved approach for
characterizing and staging primary prostate cancer.
Methods
Ten men with biopsy-confirmed prostate cancer were
recruited for the study. The mean age was 67 years
(range, 59–72 years). Blood samples were not collected
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for one patient (patient 9), and so, he was not included
in the kinetic analyses.
The imaging session included a PET/MR scan on the
Biograph mMR (Siemens Medical Solutions Inc.). After
the imaging session (18.7 ± 12.6 days), each patient
underwent a radical prostatectomy and the excised pros-
tate was sliced at 4–5 mm intervals before undergoing
tissue processing. At each interval, thin sections of the
paraffinized tissue slices were obtained by microtomy
and stained for light microscopic assessment.
Image acquisition
For PET/MR, subjects were positioned on the scanning
bed, and a 60-min dynamic PET acquisition of the pelvis
was started simultaneously with the intravenous injection
of 222 MBq 18F-choline. The radiotracer was administered
as a 1 mL bolus infused at a rate of 3 mL/s followed by a
20 mL saline flush. Venous blood samples were taken peri-
odically over the course of the PET scan. The nurse’s visits
into the scanning room to draw the blood were timed to
accommodate the various MR sequences, so as to avoid po-
tential field disturbances during the MR acquisitions. Ef-
forts were made to sample the blood at least every 10 min.
The listmode PET data were divided into 30 frames of
12 × 10, 6 × 30, 5 × 60, 4 × 300, and 3 × 600 s duration, and
each frame was reconstructed using an ordinary Poisson
ordered subset expectation maximization (OP-OSEM)
algorithm, with point spread function (PSF), with 3 itera-
tions and 21 subsets. Attenuation correction was
performed on the emission data using a multi-point T1-
weighted DIXON sequence to derive the PET 511 keV at-
tenuation map. The final image volume matrices of 172 ×
172 × 127, with voxel size of 4.173 × 4.173 × 2.031, were
post-smoothed with a 5-mm Gaussian filter.
Arterial input function
The arterial blood signal was extracted from the iliac and
femoral vessels in the image frames using factor analysis
[45, 46], which involved the calculation of the covariance
matrix for all dynamic patient voxels. Eigenanalysis was
performed on the covariance matrix and the eigenvectors
were ranked according to their corresponding eigenvalues.
The eigenvector corresponding to the blood signal was al-
ways included as one of the strongest, i.e., having one of the
largest eigenvalues, because the initial bolus peak yielded a
temporal profile which was uniquely different from the
other tissue curves. Factor image volumes were then gener-
ated by associating to each voxel, a value representing its
contribution to each signal. Figure 1 shows the maximum
intensity projections of factor image volumes for one pa-
tient. Typically, the strongest three signals comprised the
arterial blood, prostate, and bladder activity curves.
The top 40% of the voxels showing the strongest contri-
bution to the arterial signal defined the 3D volume of inter-
est (VOI) over the iliac and femoral arterial structures, and
this was projected back on the original image frames to ex-
tract the corresponding activity curve. The image-derived
blood curve was corrected for partial volume and spillover
to produce the actual arterial whole-blood activity A, which
was calculated with the following formula:
A ¼ A0−a1  Tð Þ=a2
Here, A0 is the original, uncorrected arterial blood
curve, as measured in the images, and T is the unknown
Fig. 1 Maximum intensity projection factor images representing arterial, prostate, and bladder components, with corresponding time-activity
curve signals (a). The voxels with the highest values in the vascular factor image corresponded to the iliac and femoral structures and defined the
VOI for extracting the arterial input curve (b). The first and last ten slices were omitted from the factor analyses to avoid edge noise effects
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background tissue activity, approximated by a nearby
region in muscle. The coefficients a1 and a2 correspond
to spillover and partial volume, respectively. A least-
squares fitting algorithm was employed to find the best
estimates of these coefficients, while fitting the extracted
blood curve data to the manual blood samples.
Blood-plasma partitioning and metabolite corrections
were applied to the whole-blood activity curve to calcu-
late the plasma concentration for the active tracer. As
intracellular choline uptake occurs in blood cells, the
relative plasma to whole-blood activity ratio changes
with time. This general trend was modeled by applying
the same plasma-to-whole blood ratio relationship to all
patients, starting with 1.3 at injection and decreasing
linearly to 1.1 at 60 min (Adriaan Lammertsma, personal
communication, July 20, 2016). The plasma fractions
were measured in the first four patients, and the ap-
proximation was found to be reasonable. In this work,
the plasma parent fraction was not measured; the
metabolite curve applied to all patients was similar to
that found in previous work [47]. An example of the
input curve fitting is shown in Fig. 2 for a patient with
eight manual blood samples. Additionally, the blood
sampling data for the first four patients are included in
Additional file 1: Figure S1.
PET analyses and kinetic modeling
Regions of normal and focal tracer uptake were identi-
fied in the prostate and normal uptake in muscle tissue,
and 30% threshold VOIs were drawn in the last frame of
the dynamic series, i.e., images over 50–60 min. This
threshold was found to provide acceptable delineation
for all tumor foci, and if bladder expansion caused
significant movement of the prostate, the VOIs were
reregistered in each frame. The tissue time-activity data
were weighted by frame length and fit using a 2-tissue
model to estimate four compartmental rate parameters
and blood volume fraction (VB). For the kinetic model-
ing and batch analyses, a combination of PMOD Kinetic
Modeling Tool version 3.6 (PMOD Technologies Ltd.)
and in-house developed software was used.
Selected prostate regions were confirmed histologically
as tumor and healthy tissue, and the corresponding
perfusion-related parameter K1 and tracer influx param-
eter for each, defined as
K i ¼ K1  k3k2 þ k3 ;
were correlated with respective 60-min SUV and Patlak
analysis collectively for all tissue groups. Additionally, Ki
was correlated with SUV and Patlak within each tissue
group separately.
Histologic correlation
The excised prostate glands were fixed in 4% buffered
formalin before undergoing gross dissection. The
formalin-fixed prostate specimens were cut into slices of
Fig. 2 Example of arterial 18F-choline activity concentration curves. The image-derived blood activity (dashed line) was taken from the iliac and femoral
vessels. The scaled whole-blood curve (dash-dot line) was found by correcting the image-derived curve for partial volume and tissue spillover while
simultaneously scaling it to the manual venous blood samples (triangles). The plasma concentration (solid line) was calculated by applying the plasma
partitioning coefficient and metabolite correction to the scaled whole-blood activity
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approximately 4 mm thickness, with each slice under-
going tissue processing in its own cassette. After tis-
sue processing, the prostatic tissue was embedded in
paraffin in large blocks (megablocks) and sectioned at
3 μm thickness. The sections were mounted on large
slides and were stained with hematoxylin and eosin
(H&E) before undergoing microscopic evaluation. The
tumor tissue was delineated on each slide and
assigned modified Gleason grades and an overall
Gleason score [48]—this is illustrated in Fig. 3 for a
tumor with Gleason score 4 + 3.
The diagnosis of prostatic adenocarcinoma in each
case was made by application of well-known microscopic
criteria [49]. Prostatic adenocarcinoma can have a var-
iety of microscopic patterns, and these patterns also
contribute to the grade of the tumor. In general, pros-
tatic adenocarcinoma tends to consist of malignant acini
which are smaller than the adjacent benign acini, and
which tend to infiltrate between these benign acini. The
malignant acini may also have irregular or elongated
contours and may fuse into cribriform structures or
solid sheets of cells, among other patterns.
In addition to the routine clinical work-up, the path-
ologist was asked to follow a sector-based reporting
scheme, consistent with the radiologist PI-RADS report.
Tumor regions, with their associated Gleason score,
were manually delineated within the anatomical map,
facilitating the direct coregistration between regions of
interest in PET and histopathology; this approach was
similar to that used in previous works [40, 43, 44].
Fig. 3 18F-Choline PET frame at 12.5 min fused with T2-weighted image (a). Focal tracer uptake is seen in the left lateral lobe. Histology confirmed
tumor at this region with Gleason score 4 + 3 (b). No visible uptake was seen in the contralateral, lower grade tumor tissue (Gleason score 3 + 4)
Fig. 4 Tissue time-activity curves shown for all included tissue regions, eight in tumor, nine in healthy prostate, and ten in muscle. Tissue curves for tumors
plateaued or increased throughout the duration of the scan, but in most cases, those for healthy prostate peaked within the first 5 min, then plateaued or
decreased. Muscle activity curves were much lower but always showed slight increases with time. Curves were time-shifted to match plasma input peaks
and each plot shows a different ordinate scale in order to highlight tissue trends. For this and subsequent plots, tumors are respresented by triangles,
healthy prostate by diamonds and muscle by squares
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Results
Focal 18F-choline uptake was identified in eight pros-
tates, which were confirmed tumors by histology with 3
having Gleason score 3 + 4 (though one of these was
from patient 9, without blood sampling, and was omitted
from the analyses), 1 with 3 + 5, and 4 with 4 + 3. These
and regions of healthy prostate tissue in eight patients
were delineated with threshold VOIs. Tumors were not
visualized in two patients by PET—histology reports
showed the volumes of the largest tumors were less than
0.05 cm3 in both cases. Hence, the uptake trends of the
tumors in these patients were not analyzed. For com-
parison to non-prostatic tissue, muscle activity curves
were also measured for all patients.
Overall patterns in tissue uptake were identified. 18F-cho-
line activity curves were relatively high in prostatic tumors,
and all curves in tumor tissue either plateaued around
5 min or showed slightly increasing uptake throughout the
scan. Uptake also peaked early in healthy prostate tissue,
but the curves generally plateaued early or showed slight
decrease throughout the scan. This trend was observed in
all nine prostates, except for one, which showed only
slightly increasing activity. For all measured prostate re-
gions, 18F-choline was rapidly transported from the vascu-
lar to intracellular space and metabolized—the majority of
the tissue uptake occurred within the first 3 min. Extrac-
tion to muscle was also quick, but, in all cases, the tissue
activity curves increased continuously throughout the scan.
Muscle uptake was much lower than tumor and healthy
prostate. All time-activity curves included in the analyses
are shown in Fig. 4.
Fully quantitative PET analyses using a 2-tissue com-
partmental model, accounting for blood volume, were
performed on all tissue activity curves over 60 min. The
individual values of K1–k4 for all tissue regions are given
in Table 1. The standard errors on the parameter estima-
tion, derived from the covariance of the model Jacobian
at the solution, are also given in the table—they are
expressed as the percentage of the corresponding
parameter values. The standard error defines the confi-
dence in the estimation precision; a large error may
imply that the imposed model is not appropriate for
the data. However, even when the errors were high
on the individual parameters, the corresponding er-
rors on the net influx macroparameters were gener-
ally low because of interparameter correlation. Mean
compartmental influx parameters were 0.28 ± 0.21 for
the tumors, 0.11 ± 0.04 for the healthy prostates, and
0.04 ± 0.01 for muscle.
Patlak analyses were also performed on the same time-
activity curves and SUVs recorded. Patlak linear regres-
sion fits used the dynamic data after 10 min, and SUV
values were calculated by multiplying the tissue activity in
the last (50–60-min) frame by the patient weight and div-
iding by the time-corrected injection activity. Patlak slope
and SUV were 0.22 ± 0.15 and 6.6 ± 3.2 for the tumors,
0.09 ± 0.04 and 2.8 ± 0.8 for the healthy prostates, and
0.04 ± 0.01 and 1.2 ± 0.16 for muscle, respectively. The
numbers for each patient are given in Table 2.
The tumor data in this table is represented graphically in
Fig. 5, where the three key numerical parameters, K1, Patlak
slope, and SUV, are plotted as a function of Gleason score.
The correlations between SUV and Patlak analysis and
compartmental tracer kinetic modeling were evaluated,
using K1 and macroinflux parameter Ki as figures of
merit. Correlation of the simplified methods with Ki was
better than that with K1, shown in Fig. 6. The regression
fit is displayed on each respective plot, along with the
coefficient of determination and p value. Significance
was calculated using a one-tailed F test against the null
hypothesis of no correlation.
The good correlation observed was largely attrib-
uted to the relatively large intertissue range of values
used for the regression fit, especially for SUV. Hence,
the correlations were generally poorer within individ-
ual tissue groups. Patlak influx, however, still per-
formed relatively well with respect to kinetic influx
parameter Ki, as seen in Fig. 7.
Table 2 Various metrics (with %SE) from PET analyses of healthy prostate and tumor tissue
Healthy prostate Tumor
Patient Tracer flux Patlak slope 60-min SUV Tracer flux Patlak slope 60-min SUV Gleason score
1 0.1 (2.7%) 0.08 (3.2%) 2.9 0.15 (1.4%) 0.12 (3.1%) 4.3 3 + 4
2 0.12 (2.6%) 0.1 (3.2%) 2.8 – – – –
3 0.04 (32.6%) 0.03 (12.1%) 1.4 0.26 (7.3%) 0.22 (2.5%) 7 4 + 3
4 0.08 (8.6%) 0.05 (5.4%) 3 0.14 (4.3%) 0.12 (2.6%) 6.2 4 + 3
5 0.15 (6.5%) 0.16 (3.9%) 3.8 – – – –
6 0.17 (3.7%) 0.12 (5.6%) 3.7 0.44 (2.6%) 0.4 (1.5%) 10.7 4 + 3
7 0.14 (4.5%) 0.11 (3.7%) 2.8 0.14 (0.7%) 0.12 (1.6%) 2.9 3 + 5
8 – – – 0.7 (16.5%) 0.48 (3.4%) 10.9 4 + 3
10 0.08 (4.9%) 0.06 (3.4%) 2.3 0.14 (2.8%) 0.12 (1.7%) 4.2 3 + 4
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The effect of scan time on the estimation of the com-
partmental rate parameters was investigated. The abso-
lute bias on the estimates of K1–k4 and Ki for all tissue
regions, relative to those at 60 min, is shown in Fig. 8.
Relative bias on the k2–k4 parameter estimates was ob-
served for the shorter scan times, but K1 and Ki showed
more stability, with mean biases at 3.6 and 7.4% and
12.1 and 44.2% at 30- and 10-min scan times,
respectively. The relationship between the Ki flux values
from the 60-min scan and those calculated using only
the first 30 and 10 min of dynamic data was investigated,
and the correlation for each tissue group is shown in
Fig. 9.
For all tissue groups, the data showed that choline influx
parameters, calculated with 30 min of dynamic data, were
significantly well correlated with those of the full 60 min.
Fig. 6 Correlation between fully quantitative compartmental modeling using K1 (left plots) or macroinflux parameter Ki (right plots) and simplified methods
SUV (row A) and Patlak (row B) across all tissues. Ki showed better correlation with the simplified methods than K1. However, the good correlations
observed between Ki and both SUV and Patlak were mainly attributed to the relatively large intertissue range of values used for the regression fit. Points
corresponding to tumor activity are represented by triangles, those from healthy prostate tissue are diamonds, and muscle are squares
Fig. 5 Choline uptake metrics in tumor and healthy prostate. Intrapatient choline uptake was significantly higher in tumors with Gleason score of 4 + 3
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Discussion
This work investigated 18F-choline uptake patterns in
prostatic tumors, healthy prostate tissue, and muscle;
tracer kinetic analyses were performed with compart-
mental modeling. Plasma input functions were obtained
through image-derived methods, fit to manual blood
measurements while accounting for partial volume and
spillover effects, and corrected for plasma partitioning
and metabolites. Correlations were evaluated between
the influx rate parameter calculated from fully quantita-
tive analyses and Patlak and 60-min SUV.
A limitation of this study is that arterial blood was not
collected from the subjects, so accurate measurements of
the radiolabeled metabolites were not possible. Hence, we
applied a single metabolite correction to all plasma curves.
This method, however, is not ideal, since high interpatient
variability in the parent tracer fraction has been reported
[41] which could lead to errors and bias in the estimations
of the rate parameters. To characterize these effects, we
systematically ran the curve fitting algorithm on all tissue
data with different metabolite corrections [41, 47, 50] and
corresponding plasma inputs. We found that there were
indeed rather large variances on some of the estimations
of the individual microparameters K1–k4, but that the cal-
culations of the macroflux parameter Ki were robust. A
similar investigation was performed to assess the effect of
the plasma partitioning. For the first four patients with
manual blood sampling, the kinetic parameters estimated
using the linear partitioning method used here were com-
pared to those estimated using the mean of the individual
patient measurements as a constant partitioning ratio.
Again, we found that the estimates of the individual com-
partmental rate parameters were far more sensitive to this
than the calculated tracer influx. Plots showing the results
of both of these tests are shown in Additional file 1:
Figures S2 and S3.
Regarding the choice of compartment model, we ran
the curve fitting algorithm on all tissue data using four
different models: 1T1k+Vb, 1T2k+Vb, 2T3k+Vb, and
2T4k+Vb. The most appropriate compartmental model
to characterize choline kinetics was chosen based on the
mean value of the Akaike information criterion (AIC)
[51] calculated for all tissue curves (Additional file 1:
Figure S4), and this was found to be the 2T4k+VB com-
partmental model. However, the Akaike weight was only
just the lowest with this model—in fact, half of the tissue
Fig. 7 Correlation between influx parameter Ki and SUV (row A) was relatively poor within individual tissue groups compared to that in the total
sampled tissue population, shown in Fig. 6. Good correlations were however, generally observed between compartmental modeling and Patlak
slope (row B), showing the validity of a simplified Patlak model as a substitute for the more complex compartmental analysis
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curves preferred the 2T3k+Vb model, and different
choices of input model may have led to small differences
in this result. The use of a reversible model is not con-
sistent with previous works which have reported irre-
versible tracer kinetics in tissue—indeed, the k4 values
were found to be very small compared to the other pa-
rameters. So, even though the AIC analyses suggested a
model which did not constrain k4 to be zero, the net in-
flux rates were still well correlated with those of Patlak
analyses. The 2T4k+VB model performed well overall,
but in some cases, it rendered the fitting algorithm un-
able to find the global minimum, especially in the
muscle regions where the slow monotonically increasing
uptake was better represented by an irreversible model.
Fitting the data to a model with too many parameters
produced unstable estimates on parameter values, as
seen in Table 1. This is consistent with previous work
which reported that the 2T3k+Vb model provided the
lowest AIC, but a 1T1k+Vb compartmental model may
be best to quantify 18F-fluoromethylcholine due to its
robustness [41]. We were however unable to achieve re-
liable fits for all tissue data with this model, as illustrated
in Fig. 10. This is probably due to the different regions
investigated, since we found that different tissues may
require different models, even within the same subject.
The parameters that were evaluated to characterize
choline uptake in tissue were SUV, K1, Ki, and Patlak
slope. The most relevant result of this study is that SUV,
K1, Ki, and Patlak slope are indeed strong indicators of
aggressive tumor in the prostate. As can be seen in Fig. 5,
while all three parameters show limited correlation with
Gleason score for low-grade tumors, they all show a dra-
matic increase at Gleason score 4 + 3. This could suggest
that SUV, and even better Ki and Patlak slope, could be
used as indicators of aggressive tumors. Micropara-
meters k2, k3, and k4 showed no correlation with Gleason
score (results not reported). However, it is possible that
these kinetic parameters could be more helpful in PET
imaging with tracers other than choline.
It is well known that choline is rapidly transported and
phosphorylated within the cells [39], and indeed, we ob-
served that the majority of the tissue tracer uptake oc-
curred within the first 5–10 min. Hence, this work
investigated the effects of scan time reduction on the
quantitative analyses. Here, we found that the calculation
variability in the microparameters k2–k4 was sensitive to
Fig. 8 Absolute estimation bias on kinetic rate parameters of all tissue regions for various dynamic scan times, relative to those at 60 min. Shorter scan
times introduced bias in estimates of parameters k2–k4. However, K1 and the macroinflux parameter Ki were relatively stable. For all parameters, 30 min
of scan data seemed acceptable for accurate estimation
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the scan time but estimates of perfusion and choline
transport, represented by K1, and the macroflux parameter
Ki were more stable; this finding is not uncommon for
compartmental modeling tasks. This notwithstanding, ac-
curate characterizations of 18F-choline influx for all tissue
could be quantified using 30 min of dynamic scan data, as
can be appreciated in Figs. 8 and 9. Further, the Ki correla-
tions we found were comparable to those reported by
Verwer et al. for scan durations 40 vs. 10 min, 40 vs.
20 min, and 40 vs. 30 min. Our correlation slopes for the
same times were 1.2, 1.1, and 0.99 and those from Verwer
et al. were 0.93, 1.05, and 1.03. Our R2 values were 0.93,
0.95, and 1, and those from Verwer et al. were 0.97, 0.9,
and 1. These findings may prove useful for future studies
investigating dynamic 18F-choline PET for prostate appli-
cations, since scan time should be kept to a minimum for
patient convenience and scanner throughput consider-
ations and also to avoid bladder filling issues (which is not
a consideration for the 11C-labeled derivative). Motion is
not typically a major problem with pelvic scanning, but
expansion of the bladder can cause deformation of the in-
ternal structures, affecting the voxel measurements over
time. Shorter scan times would minimize these effects.
Fig. 9 The choline influx parameter Ki values calculated for the entire 60-min scan were correlated with those calculated using only the first portion of
dynamic data. Good correlation was still seen in all tissue groups for the 30-min data, with slopes near 1. The 10-min data showed relatively good
correlation for tumor but poor correlation for healthy prostate and muscle
Fig. 10 Comparison of different compartmental models, 1T1k+VB is
dashed line and 2T4k+VB is solid. The 1-tissue model could not accurately
fit the 18F-choline data in all tissue groups. Tumor data are triangles,
healthy prostate data are diamonds, and muscle are squares
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An important result of this work is the development
of a method and a protocol to perform kinetic studies of
prostate cancer tracer in primary tumor and perform
correlation between compartmental model parameters
and Gleason score. We plan to apply these methods with
other newer and more specific tracers for prostate can-
cer, with the purpose of correlating aggressiveness of the
disease and PET imaging parameters, therefore provid-
ing a non-invasive method for supporting staging and
therapy planning of primary tumor.
Conclusions
This study of the kinetics of 18F-choline, using both Patlak
method and fully compartmental modeling, showed a
strong correlation between Ki and Patlak slope in tumor
tissue; K1 and SUV were also correlated to a lesser degree.
Due to differences in 18F-choline uptake profiles for differ-
ent tissues, a 2-tissue model was needed to quantify tracer
uptake. Fully quantitative analyses were performed for ac-
curate characterization of the tissue uptake, but this work
showed that reliable estimates of all kinetic parameters
can be achieved with only 30 min of dynamic data. Finally,
an interesting result of this study is that even if SUV, K1,
Ki, and Patlak slope are poor differentiators of low-grade
tumor compared to healthy prostate tissue, they are strong
indicators of aggressive disease: they all dramatically in-
crease at Gleason score 4 + 3. The good correlation be-
tween Ki as determined from the compartment model and
from the Patlak analyses indicates that the Patlak plot can
be used as a substitute for full compartmental analysis of
the 18F-choline data in the prostate.
Additional file
Additional file 1: Figure S1. Venous blood sampling points for four
patients. These data were consistent with the plasma partitioning model
applied to all subjects in this work. Figure S2. Compartmental model
rate parameters were independently estimated using five different
metabolite correction models (a). Mean values are shown for all tissue
regions in all patients (b); diamonds represent regions of healthy prostate
and triangles represent tumors—with different colors corresponding to
different Gleason scores. Error bars show the standard deviation of the
results obtained with the four metabolite corrections. Calculations of the
macroinflux parameters were more robust to changes in the input profile
than were the individual compartmental parameters. Figure S3.
Compartmental model rate parameters were independently estimated
using two different plasma partitioning models for the first four patients
with manual blood sampling; diamonds represent regions of healthy
prostate and triangles represent tumors—with different colors
corresponding to different Gleason scores. Error bars show the standard
deviation of the results obtained with the two partitioning methods.
Similar to the results shown in Additional file 1: Figure S2, estimations of
choline influx rates were less sensitive than were the individual
parameters. Figure S4. Akaike information criterion analysis for all tissue
regions. Four different compartmental models were used to fit the data
and the best model was determined by the lowest total AIC score. This
plot shows mean AIC values in each of the three tissue regions; error
bars show the interpatient standard deviation in each tissue category.
The 2T4k+vB model (slightly) yielded the lowest overall AIC, but the
reversible k4 parameters were generally small compared to the other
parameter values. Good correlation was still observed between choline
influx terms, calculated from this model and Patlak analyses. Figure S5.
Example patient maximum intensity projection image shown with 3D
delineated tissue regions: red is tumor, green is healthy prostate, and
blue is muscle. (DOCX 260 kb)
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